ZEISS concludes fiscal year for the first time with revenue over 10 billion
Media OutReach
2023-12-19 17:00
Already collect
Contents Provided by Media OutReach
- Exceptional growth with contributions from all four segments - Expenditure in research and development amounted to 15% of revenue - Around 43,000 employees globally, up 11% on the prior year - Around 3.5 billion euros in investments in infrastructure planned for the next 5 years worldwide - around 3 billion of which to be invested in Germany - Transformation into a data- and process-driven organization
OBERKOCHEN, GERMANY - Newsaktuell - 19 December 2023 - The ZEISS Group was able to continue its dynamic revenue growth with a growth rate at the very high level of the prior year. In fiscal year 2022/23 (reporting date: 30 September 2023), revenue rose to over 10 billion euros for the first time in the company's history (prior year: 8.8 billion euros, up 15%). Earnings before interest and taxes (EBIT) were also up on the previous year at 1.7 billion euros (prior year:1.6 billion euros). All four segments of the ZEISS Group contributed to this growth despite the challenging market environment.
Segment development
"We can look back on another very successful fiscal year. To be able to continue this dynamic growth path in the future, we need to set the right course now. We are doing this by investing huge sums in our further development," said Dr. Karl Lamprecht, President and CEO of ZEISS. "Our success is based on our distinctive innovative strength. To ensure this continues, we have invested 15% of revenue in research and development, personnel development, and infrastructure – more than ever before."
Hashtag: #ZEISS
The issuer is solely responsible for the content of this announcement.
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling 10 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (status: 30 September 2023).
Latest comments